Yervoy (ipilimumab) is a biologic drug used for the treatment of advanced melanoma. It works by stimulating the immune system to attack cancer cells. According to Drug Patent Watch [1], the patent for Yervoy expired on March 25, 2022. This means that generic versions of the drug may become available, which could lower the cost of treatment.

Bristol-Myers Squibb, the manufacturer of Yervoy, offers financial assistance programs for eligible patients who need help paying for their medication [2]. These programs include co-pay assistance, patient assistance, and free medication for uninsured patients. Patients can check their eligibility and apply for these programs through the Bristol-Myers Squibb website.

Discounts for Yervoy and another skin cancer drug, Zelboraf, were used to persuade the UK's National Institute for Health and Care Excellence (NICE) to recommend the drugs for use in the National Health Service (NHS) [3]. However, it is important to note that the availability and extent of discounts may vary depending on the country and the healthcare system.

In summary, while the patent for Yervoy has expired, Bristol-Myers Squibb offers financial assistance programs for eligible patients. The availability and extent of discounts may vary depending on the country and the healthcare system. Patients can check their eligibility and apply for these programs through the Bristol-Myers Squibb website.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.bms.com/patient-and-caregivers/get-help-paying-for-your-medicines.html
[3] http://www.pmlive.com/pharma_news/discounts_persuade_nice_to_recommend_skin_cancer_drugs_yervoy_and_zelboraf_445335